Cipla recalls over 20000 packs of inhalation drug in US
New Delhi: Pharmaceutical giant Cipla is recalling more than 20,000 packs of an asthma medication in the U.S. market, according to the U.S. Food and Drug Administration (USFDA).
In its Enforcement Report, the USFDA disclosed that Cipla USA, Inc., the subsidiary of the Mumbai-headquartered company, is recalling 20,352 packs of Ibuterol Sulfate Inhalation Aerosol, a drug prescribed for treating asthma and certain types of chronic obstructive pulmonary disease (COPD).
The company is recalling the inhalation drug due to "Failed Stability Specifications", it stated.
Medical Dialogues team had earlier reported that US-based arm of Cipla recalled 1,875 boxes of Lanthanum Carbonate chewable tablets (1000 mg, 10-count bottle) in the American market due to complaints of broken tablets.
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. The company strengths lies in the respiratory, anti-retroviral, urology, cardiology, antiinfective and CNS segments. Cipla 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets.
Read also: CDSCO Panel Clears Cipla's Glycopyrronium-Formoterol Inhaler for Phase IV Trial
